Hims vs PeptidesRx
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Hims
Best for mainstream telehealth GLP-1 accessStarting at $199/mo
PeptidesRx
Best for patients prioritizing regulatory compliance in the compounded spaceStarting at $169/mo
Side-by-Side Comparison
| Feature | Hims | PeptidesRx |
|---|---|---|
| Overall Score | 7.4/10 | ✓7.9/10 |
| Starting Price | $199/mo | ✓$169/mo |
| Customer Rating | — | — |
| Features | 2 features | ✓6 features |
| States Available | 50 | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Hims
Pros
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
PeptidesRx
Pros
- ✓Compliance-focused positioning vs gray-market vendors
- ✓Board-certified medical director
- ✓Transparent pricing with no surprise fees
- ✓Real prescriptions, not research-chemical channel
Cons
- ✗Smaller scale than Henry Meds or Hims
- ✗Wide peptide menu may distract from GLP-1 focus
Our Verdict
PeptidesRx edges out Hims with a higher overall score of 7.9/10 and is particularly strong for patients prioritizing regulatory compliance in the compounded space. Hims remains a solid alternative, especially if you're looking for mainstream telehealth GLP-1 access.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.